首页> 外国专利> ORAL PREPARATION FOR PROMOTING EXPRESSION OF TGF-β, ORAL PREPARATION FOR INHIBITING PRODUCTION OF PAIN-MEDIATING SUBSTANCE, AND ORAL PREPARATION FOR PREVENTING EDEMA

ORAL PREPARATION FOR PROMOTING EXPRESSION OF TGF-β, ORAL PREPARATION FOR INHIBITING PRODUCTION OF PAIN-MEDIATING SUBSTANCE, AND ORAL PREPARATION FOR PREVENTING EDEMA

机译:促进TGF-β表达的口服制剂,抑制疼痛介质的生产的口服制剂以及预防水肿的口服制剂

摘要

An oral preparation for promoting the expression of TGF-β comprises hyaluronic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and can promote the expression of TGF-β in plasma. An oral preparation for inhibiting the production of a pain-mediating substance comprises hyaluronic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and can promote the expression of TGF-β in plasma to thereby inhibit the production of the pain-mediating substance. An oral preparation for inhibiting the production of a pain-mediating substance comprises hyaluronic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and can inhibit the production of PGE2 and/or bradykinin which is a pain-mediating substance. An oral preparation for preventing edema comprises hyaluronic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and can inhibit the production of PGE2 and/or bradykinin which is a pain-mediating substance.
机译:促进TGF-β表达的口服制剂包含透明质酸或其药学上可接受的盐作为有效成分,并且可以促进血浆中TGF-β的表达。抑制疼痛的物质产生的口服制剂包含透明质酸或其药学上可接受的盐作为有效成分,并且可以促进血浆中TGF-β的表达,从而抑制疼痛的物质的产生。抑制疼痛的物质产生的口服制剂包含透明质酸或其药学上可接受的盐作为有效成分,并且可以抑制作为疼痛的物质的PGE 2和/或缓激肽的产生。预防水肿的口服制剂包含透明质酸或其药学上可接受的盐作为有效成分,并且可以抑制作为疼痛调节物质的PGE 2和/或缓激肽的产生。

著录项

  • 公开/公告号WO2013129577A1

    专利类型

  • 公开/公告日2013-09-06

    原文格式PDF

  • 申请/专利权人 KEWPIE CORPORATION;

    申请/专利号WO2013JP55431

  • 申请日2013-02-28

  • 分类号A61K31/728;A61P7/10;A61P29;A61P43;

  • 国家 WO

  • 入库时间 2022-08-21 16:30:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号